SAFETY OF THE USE OF PSYCHOTROPIC DRUGS FOR COMPLICATIONS OF COVID-19

Background: The article provides information on the safety of the use of psychotropic drugs in patients with COVID=19 and their possible negative impact on the state of various organs and systems of the body. Methods: A targeted review on the issues under study was carried out based on a Pub Med search with the keywords complications of COVID=19, psychopharmacology of COVID=19, side effects. In addition, the article was supplemented with data from our own research and publications. Results: The course of a new coronavirus infection is accompanied by complications from various organs and systems of the body. Complications arise from the respiratory and cardiovascular systems, hemapoiesis, liver and kidney function, and the central nervous system. Almost all classes of psychotropic drugs can negatively affect the symptoms of COVID=19 and make the disease worse. Conclusions: When prescribing psychotropic drugs in patients with COVID=19, the possible negative effect of therapy on the course of the disease should be taken into account. In this case, it is necessary to focus on the spectrum of side effects of prescribed psychotropic drugs and correlate them with the nature of somatic disorders caused by complications of coronavirus infection. In the acute period of the disease, the appointment of high doses of benzodiazepines, TAD, carbamazepine, lithium salts and clozapine should be abandoned. Safer drugs are SSRIs, SNRIs, and second=generation antipsychotics: aripiprazole, olanzapine, risperidone.